Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/3/2019
SIETES contiene 92697 citas

 
 
 1 a 20 de 44 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Sánchez Caballero D. "Es fundamental que el cannabis terapéutico sea aprobado para avanzar en la investigación" . eldiario.es 2019:5 de marzo. [Ref.ID 103049]
2.Enlace a cita original Cita con resumen
Gobbi G, Atkin T, Zytnski T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N, Mayo N. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. A systematic review and meta-analysis. JAMA Psychiatry 2019:13 de febrero. [Ref.ID 103030]
3.Enlace a cita original Cita con resumen
Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med 2018:5 de noviembre. [Ref.ID 102851]
4. Cita con resumen
Schuster RM , Gilman J , Schoenfeld D , Evenden J , Hareli M , Ulysse C , Nip E , Hanly A , Zhang H , Evins E. One month of cannabis abstinence in adolescents and young adults is associated with improved memory. J Clin Psychiatry 2018;79:17m11977. [Ref.ID 102839]
5.Tiene citas relacionadas Cita con resumen
El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, Aaron C, King A, Chang A. Characteristics of tianeptine exposures reported to the National Poison Data System — United States, 2000–2017. Morbidity and Mortality Weekly Report 2018;67:3 de agosto. [Ref.ID 102752]
6. Cita con resumen
Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees. JAMA Intern Med 2018;178:mayo. [Ref.ID 102740]
7.Tiene citas relacionadas Cita con resumen
Thielking M. Poison control calls spike for unapproved drug that produces opioid-like highs. STAT Daily Recap 2018:2 de agosto. [Ref.ID 102737]
8.Enlace a cita original Cita con resumen
Ramaekers JG. Driving under the influence of cannabis. An increasing public health concern. JAMA 2018;319:10 de abril. [Ref.ID 102668]
9.Enlace a cita original Cita con resumen
Mammen G, Rueda S, Roerecke M, Bonato S, Lev-Ran S, Rehm J. Association of Cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. J Clin Psychiatry 2018;79:5 de junio. [Ref.ID 102666]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Olfson M, Wall MM, Liu SM, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 2018;175:enero. [Ref.ID 102495]
12.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wen H, Hockenberry JM. Association of medical and adult-use marijuana laws with opioid prescribing for Medicaid enrollees . JAMA Intern Med 2018;178:673-9. [Ref.ID 102494]
13.Enlace a cita originalTiene citas relacionadas Cita con resumen
Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Intern Med 2018;178:667-72. [Ref.ID 102493]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Hill KP, Saxon AJ. The role of cannabis legalization in the opioid crisis. JAMA Intern Med 2018;178:679-80. [Ref.ID 102492]
17. Cita con resumen
Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Affairs 2017;36:1 de mayo. [Ref.ID 101570]
18.Tiene citas relacionadas Cita con resumen
Livingston MD, Barnett TE, Delcher C, Wagenaar AC. Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015. Am J Public Health 2017;107:1827-9. [Ref.ID 101388]
19. Cita con resumen
Anónimo. Various states approve recreational, medical marijuana use. DIA Daily 2016:7. [Ref.ID 100907]
Seleccionar todas
 
 1 a 20 de 44 siguiente >>